Your browser is no longer supported. Please, upgrade your browser.
PHAS PhaseBio Pharmaceuticals, Inc. daily Stock Chart
PhaseBio Pharmaceuticals, Inc.
Index- P/E2.37 EPS (ttm)4.52 Insider Own0.40% Shs Outstand29.38M Perf Week-10.14%
Market Cap314.95M Forward P/E- EPS next Y-1.68 Insider Trans- Shs Float22.91M Perf Month-7.75%
Income-26.70M PEG- EPS next Q-0.32 Inst Own57.50% Short Float2.49% Perf Quarter-19.16%
Sales1.30M P/S242.27 EPS this Y-86.10% Inst Trans2.74% Short Ratio2.84 Perf Half Y207.16%
Book/sh1.80 P/B5.96 EPS next Y-27.30% ROA- Target Price22.33 Perf Year-
Cash/sh1.77 P/C6.07 EPS next 5Y- ROE- 52W Range2.55 - 16.65 Perf YTD246.93%
Dividend- P/FCF- EPS past 5Y- ROI-33.60% 52W High-36.64% Beta-
Dividend %- Quick Ratio14.20 Sales past 5Y- Gross Margin- 52W Low313.73% ATR0.92
Employees24 Current Ratio14.20 Sales Q/Q- Oper. Margin- RSI (14)37.83 Volatility7.47% 7.87%
OptionableNo Debt/Eq0.16 EPS Q/Q95.00% Profit Margin- Rel Volume0.25 Prev Close10.72
ShortableYes LT Debt/Eq0.15 EarningsAug 08 AMC Payout- Avg Volume201.41K Price10.55
Recom1.50 SMA20-14.51% SMA50-11.14% SMA20045.06% Volume20,863 Change-1.59%
Nov-13-18Initiated Needham Buy $18
Nov-12-18Initiated Stifel Buy $14
Nov-12-18Initiated Citigroup Buy $18
Jul-01-19 08:00AM  PhaseBio Added to Russell 2000® and 3000® Indexes GlobeNewswire +5.79%
Jun-18-19 10:14AM  SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating PhaseBio Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors PR Newswire +8.48%
07:31AM  The Daily Biotech Pulse: PhaseBio Pumped Up, Eiger Exults On Breakthrough Therapy Designation, Biohaven Slips On Stock Sale Benzinga
Jun-17-19 04:01PM  PhaseBio Announces Positive Preliminary Results from Phase 2a Clinical Trial of PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor in Older and Elderly Subjects GlobeNewswire +5.59%
May-09-19 04:01PM  PhaseBio Reports First Quarter 2019 Financial Results and Recent Corporate Progress GlobeNewswire
May-02-19 08:00AM  PhaseBio To Report First Quarter 2019 Financial Results and Recent Corporate Progress on May 9, 2019 GlobeNewswire
Apr-25-19 09:23AM  2 Ultra-High Growth Stocks to Buy Now Motley Fool +7.12%
Apr-17-19 04:00AM  PhaseBio completes $49.5M stock sale American City Business Journals
Apr-16-19 04:01PM  PhaseBio Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire +9.35%
08:05AM  Billionaires Are Betting This Could Be One Of The Biggest Industries In History ACCESSWIRE
Apr-12-19 11:20AM  PhaseBio plans $43M stock sale American City Business Journals +8.51%
Apr-11-19 09:19PM  PhaseBio Announces Pricing of Public Offering of Common Stock GlobeNewswire
Apr-10-19 07:32AM  The Daily Biotech Pulse: Amgen's Bone-Building Osteoporosis Drug Clears FDA Muster, PhaseBio Offering Benzinga -11.84%
Apr-09-19 04:45PM  PhaseBio Announces Proposed Public Offering of Common Stock GlobeNewswire +16.23%
04:30PM  Why PhaseBio's stock rose 16 percent Tuesday American City Business Journals
03:00PM  Here's Why PhaseBio Pharmaceuticals Rose as Much as 32.5% Today Motley Fool
11:24AM  PhaseBio Stock Up on Breakthrough Therapy Status for PB2452 Zacks
08:10AM  The Daily Biotech Pulse: PhaseBio Gets Breakthrough Therapy Designation, FDA Shoots Down Zogenix Epilepsy Regulatory Filing Benzinga
07:59AM  PhaseBio shares soar 28% premarket as FDA speeds path for approval of PB2452 MarketWatch
07:30AM  Dow Jones Futures: Zogenix Leads 3 Big Movers On FDA News Investor's Business Daily
Apr-08-19 04:01PM  PhaseBio Receives FDA Breakthrough Therapy Designation for PB2452 for the Reversal of the Antiplatelet Activity of Ticagrelor GlobeNewswire +17.15%
Apr-07-19 06:00PM  3 Stocks That Have More Than Tripled So Far in 2019 Motley Fool
Mar-26-19 04:01PM  PhaseBio Reports Fourth Quarter and Full-Year 2018 Financial and Business Results GlobeNewswire +32.85%
07:36AM  The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs Benzinga
Mar-25-19 04:30PM  PhaseBio Announces Term Loan of up to $15 Million GlobeNewswire
Mar-19-19 11:57AM  PhaseBio Stock Up on Positive Data From PB2452 Phase I Study Zacks
08:00AM  PhaseBio To Report Fourth Quarter and Full-Year 2018 Financial and Business Results on March 26, 2019 GlobeNewswire
Mar-18-19 07:29AM  PhaseBio's stock more than doubles after positive phase 1 trial results of ticagrelor reversal agent MarketWatch +67.47%
Mar-17-19 03:00PM  Full Results from PhaseBio Phase 1 Clinical Trial of PB2452 Published in the New England Journal of Medicine and Presented at the American College of Cardiologys 68th Annual Scientific Session GlobeNewswire
Mar-06-19 08:00AM  PhaseBio to Present at Cowen and Company 39th Annual Health Care Conference GlobeNewswire
Mar-04-19 08:30AM  PhaseBio Appoints Richard A. van den Broek to Board of Directors GlobeNewswire
08:00AM  PhaseBio Announces Acceptance of Late-Breaking Clinical Trial Submission of PB2452 Phase 1 Clinical Trial Results for Presentation at the American College of Cardiologys 68th Annual Scientific Session GlobeNewswire
Jan-25-19 07:00AM  Johnson & Johnson Is Selling These 2 Biotech Stocks +9.20%
Jan-10-19 02:54PM  A few minutes with... PhaseBio CEO Jonathan Mow American City Business Journals
Dec-18-18 08:00AM  The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J $5B Buyback Plan Benzinga +9.60%
Dec-17-18 04:30PM  PhaseBio Appoints Edmund P. Harrigan to Board of Directors GlobeNewswire -8.98%
Nov-30-18 08:25AM  The Daily Biotech Pulse: EC Nod For Shire, Mirati Gets FDA Clearance For Cancer Drug Trials, PhaseBio's First Earnings Benzinga
Nov-29-18 04:30PM  PhaseBio Reports Third Quarter 2018 Financial and Business Results GlobeNewswire
Nov-27-18 08:00AM  PhaseBio Announces Dosing of First Patient in Phase 2b Clinical Trial of PB1046 in Pulmonary Arterial Hypertension GlobeNewswire
Nov-21-18 08:00AM  PhaseBio To Report Third Quarter 2018 Financial and Business Results on November 29, 2018 GlobeNewswire +7.03%
Nov-07-18 08:00AM  PhaseBio to Present at Stifel 2018 Healthcare Conference GlobeNewswire
Oct-17-18 07:24PM  PhaseBio Announces Pricing of Initial Public Offering GlobeNewswire
01:19PM  PhaseBio's IPO: What You Need To Know Benzinga
Oct-15-18 01:10PM  IPO Outlook For The Week: E-Scooters, Drugs And Hotel Service Benzinga
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate is PB2452, which is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase I clinical trial, as well as developing for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery. The company is also developing PB1046, a fusion protein that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension. PhaseBio Pharmaceuticals, Inc. was founded in 2002 and is based in Malvern, Pennsylvania.